At least six peptide manufacturers across China, South Korea, and India disclosed SPPS reactor additions or automated synthesizer clusters between January and July 2025, with stated focus on hexapeptides and pentapeptides used in eye-care and anti-expression-wrinkle applications. Average quoted lead times for validated catalog sequences dropped from six weeks to four among tier-one suppliers participating in an independent buyer survey.

Capacity expansion alone does not guarantee audit readiness. Buyers report that facilities scoring highest on vendor scorecards pair throughput gains with unchanged release testing—orthogonal identity confirmation, retained samples, and documented change control when switching resin lots. Dual-sourcing remains standard: a regional supplier for agility plus an export-oriented partner for cost-sensitive SKUs.

Recommendation: reconfirm synthesis validation status and impurity profiling whenever a supplier shifts a SKU to a new production suite, even if the trade name and INCI designation are unchanged.